Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > SBM could double in a heartbeat

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Sep 30, 2024 4:24pm

114 Views

Post# 36247331

RE:RE:RE:RE:RE:RE:RE:RE:SBM could double in a heartbeat

And their opening statement on the financials posted on the website. I definitely stand corrected!
My apologies!

1
SIRONA BIOCHEM CORP.
(A Development Stage Company)
MANAGEMENT’S DISCUSSION AND ANALYSIS
FOR THE NINE MONTHS ENDED JULY 31, 2024
ITEM 1.1 INTRODUCTION
The following Management Discussion and Analysis (“MD&A”) was prepared as of September 30, 2024 and should be read in conjunction with the consolidated financial statements and related notes for the period ended July 31, 2024 which have been prepared in accordance with International Financial
Reporting Standards.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages